-
50m 10s
-
2m 50sPart 7 Close and Key Takeaways
-
3m 45sPart 1 Welcome and Introduction
-
57m 27s
-
53m 54s
New Horizons in Cardio Kidney Disease, is a new one-day virtual educational event that took place live on 30 June 2026, designed to address current challenges in cardio-kidney care through practical, cross-disciplinary education, with a focus on biomarker-guided risk assessment, optimisation of blood pressure and cardio-kidney therapies, and emerging multimodal strategies.
Led by course directors Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US), Dr Neha Pagidipati (Duke Clinical Research Institute, Durham, US), and Prof Smeeta Sinha (Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK), the programme features expert-led presentations, case-based discussions, and multidisciplinary panel sessions. This interactive, collaborative format reflects real-world care pathways and supports the wider implementation of evidence-based strategies in clinical practice.
Watch the full on-demand series* to stay at the forefront of cardio-kidney disease management and enhance your practice with the latest clinical insights.
*Please note, the live version of New Horizons in Cardio Kidney Disease was accredited. This on-demand version is not.
The symposium 'Clinical Utility of eGFR Slope Across Cardio-Kidney Care and Trial Design' is also available to watch here (This session is not intended for UK based HCPs).
Key Learning Objectives
- Increase confidence interpreting albuminuria and integrating biomarkers into risk models
- Improve confidence interpreting BP phenotypes and organ-injury signals to inform escalation decisions
- Improve understanding of therapy sequencing and combination approaches
- Greater adoption of multidisciplinary care pathways
- Enhance readiness for emerging multimodal strategies
Target Audience
- Cardiologists
- Nephrologists
- Primary Care Physicians
- Diabetes Specialists
- Endocrinologists
More from this programme
Part 1
New Horizons in Cardio Kidney Disease: Welcome and Introduction
Neha Pagidipati (Durham, US) and Smeeta Sinha (Salford, UK) introduce the programme and share the key learning objectives.
| 1 session | |
| Welcome and Introduction | Watch now |
Part 2
Session 1: Defining Persistent Risk in Cardio Kidney Disease
Neha Pagidipati (Durham, US) chairs the first session, where faculty focus on defining persistent risk in cardio-kidney disease and exploring the mechanisms that have the greatest relevance for clinical practice. She is joined by Katherine Tuttle (Seattle, US), Erika Jones (Cape Town, SA) and Shelley Zieroth (Winnipeg, CA) for presentations and panel discussion.
Part 3
Session 2: Biomarkers That Guide Decisions
Smeeta Sinha (Salford, UK) chairs this session which demonstrates how biomarkers can identify high-risk patients earlier and enable more informed treatment decisions. She is joined by Navdeep Tangri (Winnipeg, CA), Neha Pagidipati (Durham, US) and Alta Schutte (Sydney, AU) for presentations and panel discussion.
Part 4
Session 3: Optimising Care, From Guidelines to Practice
Muthiah Vaduganathan (Boston, US) chairs this session, which translates risk identification into risk reduction by exploring therapeutic classes and strategies within the context of guideline-directed care, residual risk, and multimodal protection. He is joined by Biykem Bozkurt (Houston, US), Anjay Rastogi (Los Angeles, US) and Hiddo J L Heerspink (Groningen, NL) for presentations and panel discussion.
Part 5
Session 4: Coordinating Multidisciplinary Cardio Kidney Risk Management
Neha Pagidipati (Durham, US) chairs this session and is joined by Anjay Rastogi (Los Angeles, US), Muthiah Vaduganathan (Boston, US) and Smeeta Sinha (Salford, UK). The session explores how multidisciplinary care can improve outcomes.
Part 6
Session 5: Case-Based Decisions Translation
Muthiah Vaduganathan (Boston, US) chairs the final session, a case-based panel discussion that brings together key themes from the previous sessions. A global multidisciplinary panel featuring Jeff Borenstein (Los Angeles, US), Biykem Bozkurt (Houston, US), Erika Jones (Cape Town, SA), Nicholas Jones (Oxford, UK) and Katherine Tuttle (Seattle, US) share their perspectives.
The panel review a case of a 72-year-old male patient. Beyond the case discussion, the panel explore applying biomarker findings to real-world decision-making, navigating therapy sequencing in patients with residual cardio-kidney risk, and identifying multidisciplinary decision points across cardiology, nephrology, and primary care.
Part 7
New Horizons in Cardio Kidney Disease: Close and Key Takeaways
Muthiah Vaduganathan (Boston, US) brings New Horizons in Cardio Kidney Disease 2026 to a close, sharing key insights and takeaways from the day.
| 1 session | |
| Close and Key Takeaways | Watch now |
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a cardiologist and clinical trialist based in Boston, Massachusetts, US, He practices at Brigham and Women’s Hospital and holds an academic appointment at Harvard Medical School. Dr Vaduganathan is internationally recognised for his work at the intersection of cardiovascular, kidney, and metabolic disease, with a particular focus on translating evidence from large-scale clinical trials into routine clinical practice.
Dr Vaduganathan completed his medical training in the US and pursued advanced postgraduate training in cardiovascular medicine, with a focus on heart failure and preventive cardiology. His academic development has been closely aligned with outcomes research, trial methodology, and translational science, positioning him as a leading investigator in cardio-kidney-metabolic therapeutics.
Dr Vaduganathan is widely recognised for his prolific contributions to cardiovascular research and clinical trial leadership. His work has…
Anjay Rastogi
Professor and Clinical Chief of Nephrology
Dr Anjay Rastogi is Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine UCLA in Los Angeles, California. Dr Rastogi is recognised as a pioneer in the early treatment of chronic kidney disease to prevent patients’ need to transition to dialysis.
Dr Rastogi is board-certified in Nephrology and has a doctoral degree (PhD) in Pharmacology. He did his Internal Medicine residency and Nephrology fellowship at UCLA; he completed his graduate training under the mentorship of Nobel Laureate Professor Louis Ignarro, also at UCLA. Dr Rastogi is the founding Director of the UCLA Health CORE Kidney Programme. This Programme is based on the CORE values of Clinical Excellence, Outreach, Research, and Education.
Hiddo Heerspink
Clinical Pharmacologist
Prof Hiddo Heerspink’s is a Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands. He also serves as a Visiting Professor at the University of New South Wales in Sydney, Australia. Prof Heerspink's research interests include treatment strategies and therapeutic approaches for the treatment of renal and cardiovascular disease in patients with diabetes.
Biykem Bozkurt
Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America.
Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair; Vice-Chair of Department of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine.